{"id":"W2948884915","doi":"10.1038/s41591-019-0476-5","title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":326,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health; Nature","keywords":"Medicine; Dabrafenib; Melanoma; Trametinib; Pembrolizumab; MEK inhibitor; Immunotherapy; Discontinuation; Blockade; Internal medicine; Oncology; Adverse effect; Combination therapy; Targeted therapy; MAPK/ERK pathway; Vemurafenib; Immunology; Pharmacology; Cancer research; Cancer; Kinase; Metastatic melanoma; Biology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001745735,0.000266005,0.0004259272,0.0002043147,0.0001661311,0.000328238,0.0002468734,0.0002203694,0.001128733],"category_scores_gemma":[0.00009381028,0.0001237611,0.0003084545,0.0001541238,0.0001375222,0.0002897495,0.0001783696,0.0008703251,0.0002221457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003492339,"about_ca_system_score_gemma":0.0003701439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005120226,"about_ca_topic_score_gemma":0.001974318,"domain_scores_codex":[0.9999104,0.00001630541,0.000005178309,0.0000132649,0.00002009404,0.00003479901],"domain_scores_gemma":[0.9999729,0.000004616799,0.000004336064,0.000003147795,0.00000246358,0.0000125152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02975356,0.008071122,0.003175928,0.0005255238,0.0004770741,0.0004745892,0.0001012772,0.00655163,0.5951959,0.001491532,0.004314034,0.3498678],"study_design_scores_gemma":[0.01663611,0.1690785,0.07269099,0.000168673,0.001823874,0.004379998,0.0002762194,0.03160855,0.6410629,0.003051793,0.05907734,0.0001450314],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873733,0.007237405,0.0007034624,0.0003749662,0.0001929236,0.00007040163,0.0001135862,0.00007958963,0.003854393],"genre_scores_gemma":[0.9963798,0.001465832,0.0004916603,0.00006988951,0.00003625384,0.00003688768,0.00008095473,0.000006140328,0.001432556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001128733,"threshold_uncertainty_score":0.003776014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.002431315230869503,"score_gpt":0.2083139023884205,"score_spread":0.205882587157551,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}